Post-earnings recap
Reported
Tue, Aug 4, 2026
EPS actual
$-6.75
EPS est.
$-7.07
EPS surprise
+4.58%
1-day move
+3.13%
Gilead Sciences reported a larger-than-expected loss per share, which typically raises concerns about profitability. However, the stock price increased by 3.13%, suggesting that investors may have reacted positively to other aspects of the company's performance or future potential, despite the disappointing EPS figure.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-6.75 | N/A | +4.58% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based on numerical results only.
Gilead Sciences, Inc. is a biotechnology company focused on developing innovative therapies for serious diseases, particularly in the areas of HIV, liver diseases, and oncology. As a key player in the health care sector, Gilead's advancements can significantly impact patient outcomes and the overall market landscape.
Last quarter
In Q1 2026, Gilead reported an EPS of $2.03, surpassing estimates by 7.69%. However, the stock price fell by 1.64% the following day, indicating mixed investor sentiment.
Management promises and guidance
EPS beat streak
8Q
EPS beat rate
100%
Avg EPS surprise
+9.35%
Avg 1-day reaction
+0.08%
Overall, expectations are cautious as Gilead prepares for its upcoming earnings report. Investors are particularly interested in how the company will address its product pipeline and revenue growth.
Bull case
If Gilead can demonstrate strong revenue growth and successful updates on its product pipeline, it could lead to increased investor confidence and a positive stock reaction.
Bear case
Conversely, if the company fails to provide clear guidance or reports disappointing revenue figures, it could lead to a negative market reaction.
The print will turn on these.
Q1
What specific revenue growth figures can Gilead provide for its key product lines?
This will help investors gauge the company's market performance and future potential.
Q2
Are there any updates on the clinical trials for new therapies?
Insights into the product pipeline can significantly influence investor sentiment and stock performance.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The Street may be underestimating Gilead's potential for revenue growth due to its strong pipeline and recent advancements in HIV therapies.
Supporting evidence
Gilead has consistently beaten EPS estimates, indicating stronger-than-expected performance.
The company's focus on innovation in its product pipeline may not be fully reflected in current market expectations.
Options pricing suggests a higher volatility expectation, which could indicate underlying investor confidence.
Key risk
If Gilead's revenue growth exceeds expectations, it could challenge the current cautious sentiment in the market.
Pre-commit to what would confirm each case.
The market is debating Gilead's ability to sustain growth amid competitive pressures and evolving treatment landscapes.
Bull confirmed if
Demonstrating revenue growth of over 10% year-over-year would confirm the bull case.
Bear confirmed if
Failing to achieve revenue growth or providing weak guidance would confirm the bear case.
What the market is pricing for the move.
Implied Move
±3.77%
Historical Avg
±1.3%
The options market is pricing in a move of approximately 3.77%, suggesting that investors expect some volatility around the earnings report.
Options are pricing ±3.8% while GILD has averaged ±1.3% over the last 8 prints — setup is pricing rich.
ATM IV
0.3%
30d HV
22.3%
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$2.2M
15,000 sh
1 insider
Net
$2.2M
Net selling
Most Active Insiders· 2 open-market trades
$2.2M
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
92.20%
of float
Insider
0.11%
of float
Holders
3,072
institutions
Top Holders· as of Jun 2026
Blackrock Inc.
121,844,108 sh · $17.9B
9.83%
2.4%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Gilead beats expectations and raises guidance, history suggests a potential stock increase of around 1.16% on the first day.
In line / cautious
If results are in line but management provides cautious commentary, the stock may experience minimal movement or slight declines.
Miss
Should Gilead miss expectations, the stock could see a decline, potentially around 1.16% based on historical patterns.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
1
1 buy·0 sells
Members
1
House only
Est. Notional
$1,001.00–$15,000.00
disclosed dollar ranges
Most Active Members
1 trade
The lines on the call that would change the story.
Recent Transactions
Oct 1, 2026 · @ $147.72
12,000 sh
$1.8M
Oct 1, 2026 · @ $148.63
3,000 sh
$445,879.50
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Vanguard Capital Management LLC
81,091,734 sh · $11.9B
6.54%
0.5%
FMR, LLC
66,870,816 sh · $9.8B
5.39%
-7.0%
State Street Corporation
61,216,552 sh · $9.0B
4.94%
2.3%
Capital World Investors
40,988,975 sh · $6.0B
3.31%
-0.7%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net buying
Recent Transactions
Traded May 6, 2026 · disclosed Jun 19, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.